NewLimit
Lucas Seninge is a Machine Learning Scientist at NewLimit, focusing on machine learning models for epigenetic partial reprogramming since January 2023. Previously, Lucas completed a doctoral program at the University of California, Santa Cruz, from September 2018 to December 2022, with a thesis centered on integrating biological knowledge with machine learning for single-cell data analysis. This work included automated single-cell annotation, development of an interpretable deep generative model, and contributions to drug response prediction frameworks. Additional experience includes roles as an ML Data Analyst at CoralGx, Visiting Scholar at the UC Santa Cruz Genomics Institute, and several traineeships in bioinformatics and cancer research. Lucas holds a Master's degree in High-Throughput Methods Applied to Biology from the University of Strasbourg and an Engineer's degree in Biotechnology from ESBS.
This person is not in any offices
NewLimit
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.